

emtricitabine/tenofovir disoproxil 200 mg/245 mg tablet (Truvada[®])
Gilead Sciences Ltd (No. 237/06)

Product Update

6 January 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Emtricitabine/tenofovir disoproxil 200 mg/245 mg tablet (Truvada[®]) is accepted for use in NHS Scotland for the treatment of Human Immunodeficiency Virus (HIV-1) infected adults in combination with other antiretroviral medicinal products. Both constituents are nucleoside reverse transcriptase inhibitors. The demonstration of the benefit of the combination emtricitabine and tenofovir disoproxil fumarate in antiretroviral therapy is based solely on studies performed in treatment-naïve patients.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 15 December 2005.

Chairman
Scottish Medicines Consortium